FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246885152> ?p ?o ?g. }

• W4246885152 abstract "Background Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway. Objectives The primary objective of this review is to assess the efficacy and tolerability of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. Search methods We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('varenicline' or 'cytisine' or 'Tabex' or 'nicotine receptor partial agonist') and 'smoking' in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, PsycINFO and CINAHL using MeSH terms and free text, and we contacted authors of trial reports for additional information where necessary. The last search was in October 2006. Selection criteria We included randomized controlled trials which compared the treatment drug with placebo. We also included comparisons with bupropion where available. We excluded trials which did not report a minimum follow‐up period of six months from start of treatment. Data collection and analysis We extracted data in duplicate on the type of participants, the dose and duration of treatment, the outcome measures, the randomization procedure, concealment of allocation, and completeness of follow up. The main outcome measured was abstinence from smoking after at least six months from the beginning of treatment. We used the most rigorous definition of abstinence, and preferred biochemically validated rates where they were reported. Where appropriate we performed meta‐analysis using the Mantel‐Haenszel fixed‐effect model. Main results We found five trials of varenicline compared with placebo for smoking cessation; three of these also included a bupropion experimental arm. We also found one relapse prevention trial, comparing varenicline with placebo. The six trials covered 4924 participants, 2451 of whom used varenicline. We identified one trial of cytisine (Tabex) for inclusion. The pooled odds ratio (OR) for continuous abstinence at 12 months for varenicline versus placebo was 3.22 (95% confidence interval [CI] 2.43 to 4.27). The pooled OR for varenicline versus bupropion was 1.66 (95% CI 1.28 to 2.16). The main adverse effect of varenicline was nausea, which was mostly at mild to moderate levels and usually subsided over time. The two trials which tested the use of varenicline beyond the 12‐week standard regimen found the drug to be well‐tolerated and effective during long‐term use. The one cytisine trial included in this review found that more participants taking cytisine stopped smoking compared with placebo at two‐year follow up, with an OR of 1.77 (95% CI 1.30 to 2.40). Authors' conclusions Varenicline increased the odds of successful long‐term smoking cessation approximately threefold compared with pharmacologically unassisted quit attempts. In trials reported so far, more participants quit successfully with varenicline than with bupropion. The effectiveness of varenicline as an aid to relapse prevention has not been clearly established. The main adverse effect of varenicline is nausea, but this is mostly at mild to moderate levels and tends to reduce with habituation. There is a need for independent trials of varenicline versus placebo, to test the early findings. There is also a need for direct comparisons with nicotine replacement therapy, and for further trials with bupropion, to establish the relative efficacy of the treatments. Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive." @default.
• W4246885152 created "2022-05-12" @default.
• W4246885152 creator A5008101890 @default.
• W4246885152 creator A5017708288 @default.
• W4246885152 creator A5053303537 @default.
• W4246885152 date "2007-01-24" @default.
• W4246885152 modified "2023-10-03" @default.
• W4246885152 title "Nicotine receptor partial agonists for smoking cessation" @default.
• W4246885152 cites W1971596397 @default.
• W4246885152 cites W1993112595 @default.
• W4246885152 cites W2011202557 @default.
• W4246885152 cites W2016300030 @default.
• W4246885152 cites W2030117810 @default.
• W4246885152 cites W2035962135 @default.
• W4246885152 cites W2051687528 @default.
• W4246885152 cites W2053457282 @default.
• W4246885152 cites W2063815728 @default.
• W4246885152 cites W2107200746 @default.
• W4246885152 cites W2113308458 @default.
• W4246885152 cites W2117389430 @default.
• W4246885152 cites W2118190133 @default.
• W4246885152 cites W2125435699 @default.
• W4246885152 cites W2127193609 @default.
• W4246885152 cites W2133374870 @default.
• W4246885152 cites W2134235644 @default.
• W4246885152 cites W2136284733 @default.
• W4246885152 cites W2141246891 @default.
• W4246885152 cites W2149018295 @default.
• W4246885152 cites W2162211101 @default.
• W4246885152 cites W2164386461 @default.
• W4246885152 cites W4211019521 @default.
• W4246885152 cites W4211247657 @default.
• W4246885152 cites W4239459413 @default.
• W4246885152 cites W4244820285 @default.
• W4246885152 cites W4253610986 @default.
• W4246885152 cites W4254811157 @default.
• W4246885152 doi "https://doi.org/10.1002/14651858.cd006103.pub2" @default.
• W4246885152 hasPublicationYear "2007" @default.
• W4246885152 type Work @default.
• W4246885152 citedByCount "82" @default.
• W4246885152 countsByYear W42468851522012 @default.
• W4246885152 countsByYear W42468851522014 @default.
• W4246885152 countsByYear W42468851522015 @default.
• W4246885152 countsByYear W42468851522016 @default.
• W4246885152 countsByYear W42468851522017 @default.
• W4246885152 countsByYear W42468851522018 @default.
• W4246885152 countsByYear W42468851522020 @default.
• W4246885152 countsByYear W42468851522021 @default.
• W4246885152 countsByYear W42468851522022 @default.
• W4246885152 countsByYear W42468851522023 @default.
• W4246885152 crossrefType "reference-entry" @default.
• W4246885152 hasAuthorship W4246885152A5008101890 @default.
• W4246885152 hasAuthorship W4246885152A5017708288 @default.
• W4246885152 hasAuthorship W4246885152A5053303537 @default.
• W4246885152 hasBestOaLocation W42468851522 @default.
• W4246885152 hasConcept C118552586 @default.
• W4246885152 hasConcept C126322002 @default.
• W4246885152 hasConcept C142724271 @default.
• W4246885152 hasConcept C170493617 @default.
• W4246885152 hasConcept C188987157 @default.
• W4246885152 hasConcept C204787440 @default.
• W4246885152 hasConcept C27081682 @default.
• W4246885152 hasConcept C2777053506 @default.
• W4246885152 hasConcept C2777301948 @default.
• W4246885152 hasConcept C2777843972 @default.
• W4246885152 hasConcept C2778938600 @default.
• W4246885152 hasConcept C2779547902 @default.
• W4246885152 hasConcept C2779908668 @default.
• W4246885152 hasConcept C2780687700 @default.
• W4246885152 hasConcept C58732023 @default.
• W4246885152 hasConcept C71924100 @default.
• W4246885152 hasConcept C98274493 @default.
• W4246885152 hasConceptScore W4246885152C118552586 @default.
• W4246885152 hasConceptScore W4246885152C126322002 @default.
• W4246885152 hasConceptScore W4246885152C142724271 @default.
• W4246885152 hasConceptScore W4246885152C170493617 @default.
• W4246885152 hasConceptScore W4246885152C188987157 @default.
• W4246885152 hasConceptScore W4246885152C204787440 @default.
• W4246885152 hasConceptScore W4246885152C27081682 @default.
• W4246885152 hasConceptScore W4246885152C2777053506 @default.
• W4246885152 hasConceptScore W4246885152C2777301948 @default.
• W4246885152 hasConceptScore W4246885152C2777843972 @default.
• W4246885152 hasConceptScore W4246885152C2778938600 @default.
• W4246885152 hasConceptScore W4246885152C2779547902 @default.
• W4246885152 hasConceptScore W4246885152C2779908668 @default.
• W4246885152 hasConceptScore W4246885152C2780687700 @default.
• W4246885152 hasConceptScore W4246885152C58732023 @default.
• W4246885152 hasConceptScore W4246885152C71924100 @default.
• W4246885152 hasConceptScore W4246885152C98274493 @default.
• W4246885152 hasLocation W42468851521 @default.
• W4246885152 hasLocation W42468851522 @default.
• W4246885152 hasLocation W42468851523 @default.
• W4246885152 hasLocation W42468851524 @default.
• W4246885152 hasOpenAccess W4246885152 @default.
• W4246885152 hasPrimaryLocation W42468851521 @default.
• W4246885152 hasRelatedWork W1576468683 @default.
• W4246885152 hasRelatedWork W1975973593 @default.
• W4246885152 hasRelatedWork W2061753073 @default.
• W4246885152 hasRelatedWork W2087040416 @default.
• W4246885152 hasRelatedWork W2139280107 @default.

• next